Andy Tsun

Andy Tsun

Company: Biotheus.Inc.

Job title: Co-Founder & Chief Scientific Officer


Finetuning the Potency & Safety of 4-1BB Agonist Antibodies By Targeting the Membrane Proximal Region 9:00 am

Unique anti-4-1BB VHH that binds to the membrane proximal domain to maintain potency and reduce toxicity risk CLDN18.2 x 4-1BB bispecific shows good safety and preliminary efficacy in CLDN18.2+ cancer patients 4-1BB bispecific platform can be further optimized with unidirectional Fc effector function towards TAAs but not 4-1BB+ cellsRead more

day: Day One

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.